Hikma launches Methylergonovine Maleate Tablets, USP


Hikma launches Methylergonovine Maleate Tablets, USP

London, 30 May 2018 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces that its wholly-owned US subsidiary, West-Ward Pharmaceuticals Corp. (West-Ward), has launched Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine®.

Methylergonovine Maleate Tablets are a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage.

West-Ward has partnered with Granules Pharmaceuticals Inc. (Granules) to launch Methylergonovine Maleate Tablets. Under the terms of the agreement, Hikma has the exclusive rights to distribute and market Granules’ Methylergonovine Maleate Tablets in the US market.

According to IQVIA, US sales of Methylergonovine Maleate Tablets, USP, 0.2mg were approximately $70 million in the 12 months ending March 2018.

Brian Hoffmann, President, Generics Division, said, “We are very pleased to be entering into a partnership with Granules, adding this important oxytocic agent to our product portfolio in the US. This partnership demonstrates our focus on improving patient’s access to high-quality, affordable medicines.”  

“This is the first product we have commercialized from our manufacturing facility in the Chantilly, VA and we are happy to have collaborated with West-Ward. The launch of generic Methergine tablets, the first generic in the market plays into our strategy of identifying patient needs and catering to them with economical alternatives.” said Ms. Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc.